Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis

Next Previous
Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions
  • Acronyms BE AGILE 2
  • Sponsors UCB; UCB Biopharma

    • Most Recent Events

    • 15 Nov 2023 5-yr results of Bimekizumab in BE AGILE and its OLE, presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of pooled analysis of studies (BE MOBILE 1, BE MOBILE 2, BE MOVING,BE MOBILE 1,BE MOBILE 2,BE AGILE, BE AGILE 2, assessing incidence of uveitis following inhibition of IL-7A in addition to IL-7F with bimekizumab in patients with Axial Spondyloarthritis were presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results of pooled analysis from NCT03928704, NCT03928743, NCT04436640, NCT02963506 and NCT03355573; presented at the 24th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top